AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Revenio Group Oyj

Director's Dealing May 11, 2022

3236_dirs_2022-05-11_5126ef48-e203-4b14-965a-e2f819307a89.pdf

Director's Dealing

Open in Viewer

Opens in native device viewer

Revenio Group Corporation: Managers' Transactions – Pekka Tammela

Revenio Group Corporation, Managers' transactions, May 11, 2022 at 3.00 p.m. (EEST)

Revenio Group Corporation: Managers' Transactions – Pekka Tammela

____________________________________________

Person subject to the notification requirement

Name: Pekka Tammela Position: Member of the Board/Deputy member Issuer: Revenio Group Oyj LEI: 743700I27E0FWSXLKK04 Notification type: INITIAL NOTIFICATION Reference number: 14602/7/6 ____________________________________________

Transaction date: 2022-05-11 Venue not applicable Instrument type: SHARE ISIN: FI0009010912 Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE

Transaction details (1): Volume: 385 Unit price: 0 N/A Aggregated transactions (1): Volume: 385 Volume weighted average price: 0 N/A

For further information, please contact

CFO Robin Pulkkinen, tel. +358 50 505 9932 [email protected] www.revenio.fi

Distribution Nasdaq Helsinki Ltd Main media www.revenio.fi

Revenio Group in brief

Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering

physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare software solutions provide eye care professionals with new innovative digital clinical tools that drive greater efficiency and enhance the quality of care.

In 2021, the Group's net sales totaled EUR 78.8 million, with an operating profit of EUR 22.1 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Attachments

Revenio Group Corporation: Managers' Transactions – Pekka Tammela

Talk to a Data Expert

Have a question? We'll get back to you promptly.